Biotech Investors Rolling the Dice with 250% SPAC Surge

Emerging biotech companies have been finding creative ways to explode onto the stock exchange during the COVID-19 pandemic. One of these is through special purpose acquisition companies (SPAC) mergers and acquisitions, which allow a desired company to go public more quickly and with less risk with than with the traditional Initial Public Offering (IPO).